These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8095115)

  • 21. Chronic rejection after concordant xenografting.
    Scheringa M; Buchner B; Geerling RA; de Bruin RW; Schraa EO; Bouwman E; IJzermans JN; Marquet RL
    Transplant Proc; 1994 Jun; 26(3):1346-7. PubMed ID: 8029935
    [No Abstract]   [Full Text] [Related]  

  • 22. Chronic rejection of rat aortic allografts. III. Synthesis of major eicosanoids by vascular wall components and effect of inhibition of the thromboxane cascade.
    Mennander A; Tiisala S; Ustinov J; Räisänen A; Paavonen T; Häyry P
    Arterioscler Thromb; 1992 Dec; 12(12):1380-6. PubMed ID: 1450170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple-drug immunosuppression significantly reduces chronic rejection in noninfected and RCMV-infected rats.
    Lemström K; Bruning J; Koskinen P; Bruggeman C; Lautenschlager I; Häyry P
    Transplant Proc; 1994 Jun; 26(3):1727-8. PubMed ID: 8030105
    [No Abstract]   [Full Text] [Related]  

  • 24. Partial inhibition of allograft arteriosclerosis (chronic rejection) by 15-deoxyspergualin.
    Räisänen-Sokolowski A; Yilmaz S; Tufveson G; Häyry P
    Transplantation; 1994 Jun; 57(12):1772-7. PubMed ID: 8016883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of growth factor synthesis and growth factor action: two possible sites of interference in allograft vessel disease and coronary bypass or balloon injury.
    Häyry P; Aavik E; Myllärniemi M
    Metabolism; 1996 Aug; 45(8 Suppl 1):101-3. PubMed ID: 8769397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58.
    Li W; Iyer S; Lu L; Buelow R; Fung JJ; Rao AS; Woo J; Qian S
    Transpl Int; 2003 Dec; 16(12):849-56. PubMed ID: 12942166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards understanding the pathophysiology of chronic rejection.
    Häyry P; Mennander A; Yilmaz S; Ustinov J; Räisänen A; Miettinen A; Lautenschlager I; Lemström K; Bruggeman CA; Paavonen T
    Clin Investig; 1992 Sep; 70(9):780-90. PubMed ID: 1450632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic rejection--graft arteriosclerosis.
    Foegh ML
    Transplant Proc; 1990 Feb; 22(1):119-22. PubMed ID: 1968687
    [No Abstract]   [Full Text] [Related]  

  • 29. Chronic graft rejection: accelerated transplant arteriosclerosis.
    Ewel CH; Foegh ML
    Immunol Rev; 1993 Aug; 134():21-31. PubMed ID: 7693578
    [No Abstract]   [Full Text] [Related]  

  • 30. Angiopeptin inhibits thymidine incorporation by explants of porcine coronary arteries.
    Vargas R; Wroblewska B; Rego A; Cathapermal S; Ramwell PW
    J Cardiovasc Pharmacol; 1997 Feb; 29(2):278-83. PubMed ID: 9057079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo.
    Räisänen A; Mennander A; Ustinov J; Paavonen T; Häyry P
    Transpl Int; 1993; 6(5):251-7. PubMed ID: 8216700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat.
    Lemström KB; Räisänen-Sokolowski AK; Häyry PJ; Koskinen PK
    Arterioscler Thromb Vasc Biol; 1996 Apr; 16(4):553-64. PubMed ID: 8624778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and experimental chronic allograft rejection.
    Häyry P; Isoniemi H; Yilmaz S; Mennander A; Lemström K; Räisänen A; Koskinen P; Ustinov J; Lautenschalger I; Taskinen E
    Transplant Proc; 1994 Jun; 26(3):1702-3. PubMed ID: 8030092
    [No Abstract]   [Full Text] [Related]  

  • 34. Rat heart smooth muscle cells express high and low affinity receptors for somatostatin-14, which are involved in regulation of cell proliferation.
    Leszczynski D; Zhao Y; Cathapermal S; Nilsson J; Foegh ML
    Life Sci; 1993; 53(22):1663-74. PubMed ID: 7901726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rat aortic allografts: an experimental model for chronic transplant arteriosclerosis.
    Häyry P; Mennander A; Tiisala S; Halttunen J; Yilmaz S; Paavonen T
    Transplant Proc; 1991 Feb; 23(1 Pt 1):611-2. PubMed ID: 1990624
    [No Abstract]   [Full Text] [Related]  

  • 36. Angiopeptin as a potent inhibitor of myointimal hyperplasia. Systemic injection and local administration via impregnation in a biodegradable polymeric gel.
    Matsuda T; Motomura N; Oka T
    ASAIO J; 1993; 39(3):M512-7. PubMed ID: 7903567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiopeptin: a treatment for accelerated myointimal hyperplasia?
    Foegh ML
    J Heart Lung Transplant; 1992; 11(3 Pt 2):S28-31. PubMed ID: 1352465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of 15-deoxyspergualin on allograft arterio-sclerosis and growth factor synthesis in the rat.
    Räisänen-Sokolowski A; Aho P; Tufveson G; Häyry P
    Transpl Int; 1994; 7 Suppl 1():S376-7. PubMed ID: 11271256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of anti-CD4 monoclonal antibody and cyclosporine A or a combination of both on chronic rejection in the rat aortic allograft model.
    Lácha J; Lehmann M; Chadimová M; Brock J; Havlícková J
    Transplant Proc; 1994 Dec; 26(6):3242-3. PubMed ID: 7998129
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanism of action of 15-deoxyspergualin in allograft arteriosclerosis in rat aortic transplants.
    Räisänen-Sokolowski A; Aho P; Tufveson G; Häyry P
    Transplant Proc; 1994 Dec; 26(6):3224. PubMed ID: 7998124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.